GLP-1 Pipeline, Coverage & Long-Term Outcomes

Oral orforglipron was approved in April 2026, Medicare coverage began July 1 at $50 per month, and retatrutide is expected to file in Q1 2027. Celltrion’s quadruple agonist CT-G32/SCO-940 showed promising comparative results only in rats; human benefit is unknown, and long-term safety, maintenance, and muscle and bone questions remain.